ZW439 / Zymeworks - LARVOL DELTA

ZW439, a novel CLDN18.2-targeting pan-RAS inhibitor antibody drug conjugate for the treatment of RAS mutated pancreatic cancer (AACR 2026) - "In vivo, ZW439 demonstrates highly efficacious anti-tumor activity in multiple CLDN18.2 expressing xenografts and has a favourable PK profile. ZW439's pan-RASi ADC drug-linker platform demonstrates encouraging tolerability, with no significant toxicity observed following dosing up to 200 mg/kg in mice.The encouraging preclinical profile of ZW439 supports its potential as a differentiated therapeutic for the treatment of Pancreatic cancer."

ADC • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor • CLDN18

ZW439, a novel CLDN18.2-targeting pan-RAS inhibitor antibody-drug conjugate for the treatment of RAS mutated pancreatic cancer (GlobeNewswire) - "Zymeworks presents new preclinical data at AACR 2026....Strong anti-tumor activity observed in CLDN18.2-expressing RAS-mutant xenograft models, at doses as low as 1 mg/kg. Target-dependent delivery of pan-RAS inhibitor payload with potent RAS pathway inhibition and cytotoxicity. Robust bystander activity supports activity in heterogeneous tumors."

Preclinical • Pancreatic Cancer